Contact

Paxman publishes newsletter on strong international order and installation activity during the summer

Today, Paxman publishes the August issue of its newsletter aimed at shareholders, investors and other interested parties.

This month’s issue highlights that Paxman has received several important orders in its international markets, and the company’s distribution partners have installed scalp cooling systems in many countries including Brazil, the Czech Republic, France, India, Israel, Puerto Rico, Spain and Sweden.

The newsletter also includes an update on Paxman’s successful webinar in India where nurses from Massachusetts’s General Hospital and Mumbai Oncocare Cancer shared their experiences from using scalp cooling with over 490 livestreaming participants, and that Paxman has received several order and installed equipment in the UK and a number of US states.

Shareholders are also encouraged to submit questions on the company’s recently published Q2 2021 interim report for a CEO interview that will be published in the newsletter for next month.

To read the newsletter and subscribe for upcoming issues, follow this link:

http://bit.ly/paxaug21en

Paxman’s investor newsletter is published monthly as a part of the company’s effort to strengthen its market communication together with the IR communication agency Honeybadger. Every published issue of the newsletter is available on Paxman’s website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

What we do
Paxman are world leaders in chemotherapy side effect management on an ambitious journey to change the face of cancer through cryotherapy-based treatments. The Paxman mission is to democratise access to scalp cooling globally.
Learn more →
Financial Information
Read the latest Paxman financial reports. In these comprehensive documents, you will find a detailed overview of our financial performance, key milestones, and a strategic outlook for the future. Reports are published quarterly and annually.
Read reports  →
Investing in Paxman
Paxman has treated 100,000+ patients and installed 5,000+ systems in more than 65 countries worldwide. We are helping to manage the trauma of chemotherapy hair loss. By investing in Paxman, you're not just supporting a company; you're joining us in changing the face of cancer.
Visit the Investor Centre →
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram